Mr. Dwight Gorham reports

INTELGENX ANNOUNCES CO-DEVELOPMENT AND COMMERCIALIZATION OF CANNABINOID-INFUSED VERSAFILM(TM) PRODUCTS WITH TILRAY

IntelGenx Technologies Corp. and Tilray Brands Inc. have entered into a further amendment to their November, 2018, licence, development and supply agreement for the co-development and commercialization of cannabinoid-infused VersaFilm products, settling IntelGenx's arbitration claim against Tilray.

Pursuant to the second amendment, IntelGenx has received an initial purchase order from Tilray for three SKUs (stock-keeping units) (CBD20, THC10, THC10/CBD10), with each SKU totalling 130,000 filmstrips. The second amendment also allows for IntelGenx's co-development and commercialization of CBD (cannabidiol) (pursuant to a previous amendment), THC (tetrahydrocannabinol) and combination THC/CBD products with additional partners. The second agreement removes any royalties paid to or from Tilray.

"This partnership and settlement represent a significant milestone in building our relations with Tilray, and we are excited to begin this new chapter of the companies making innovative cannabinoid-infused oral thin film products available to consumers," said Dwight Gorham, IntelGenx's chief executive officer.

About IntelGenx Technologies Corp.

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx's superior film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next-generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceutical services to pharmaceutical partners, including R&D (research and development), analytical method development, clinical monitoring, IP (intellectual property) and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot-scale and commercial-scale production.

We seek Safe Harbor.